ClinicalTrials.gg

Program

HEC53856

A development code. Also written as “HEC53856 tablet”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by Sunshine Lake Pharma.

Furthest: phase 2, since Oct 14, 20264 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sunshine Lake Pharma41 open or runningphase 2since Oct 14, 2026Mar 19, 2019Feb 2028phase 2 · NCT07891377

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2019First study: phase 1 study in HealthyFirst studyNCT03886688 · 116 enrolled · China
  2. May 30, 20212 phase 1 studiesNCT04925674, NCT04925661
  3. Oct 14, 2026Phase 2 study in Chemotherapy-induced AnemiaPhase 2 reachedNCT07891377 · 160 planned · China

Ahead

  1. Feb 2028Primary completion: phase 2 study in Chemotherapy-induced AnemiaNCT07891377

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07891377Chemotherapy-induced Anemia · China2Not yet recruitingFeb 2028160
NCT04925674Hemodialysis · China1CompletedOct 19, 202260
NCT04925661Renal Insufficiency, Chronic · China1CompletedAug 29, 202340
NCT03886688Healthy · China1CompletedJan 1, 2020116

How it is read

Names in the registry

  • “HEC53856”, 3 entries
  • “HEC53856 tablet”, 1 entry

Codes read as this program: HEC53856.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.